The clinical phase I study evaluated the safety and feasibility of injecting allogeneic adipose-derived mesenchymal stem cells (ASCs) into the lacrimal gland as a treatment of aqueous deficient dry eye disease (ADDE) Sjögrens syndrome.
The study found injection of allogeneic ASCs produced using Cell2Cure´s patented technology into the lacrimal gland to be safe, feasible and well tolerated in seven patients. A single injection of allogeneic ASCs improved both signs and symptoms in patients with severe ADDE due to either primary or secondary Sjögren’s syndrome.
Reference:
Møller-Hansen M, Larsen AC, Toft PB, Lynggaard CD, Schwartz C, Bruunsgaard H, Haack-Sørensen M, Ekblond A, Kastrup J, Heegaard S.
Safety and feasibility of mesenchymal stem cell therapy in patients with aqueous deficient dry eye disease.
Ocul. Surf. 2021 Jan; 19:43-52. doi: 10.1016/j.jtos.2020.11.013. Epub 2020 Nov 28.